IL143496A0 - Controlled release formulation comprising gnrh-ii - Google Patents
Controlled release formulation comprising gnrh-iiInfo
- Publication number
- IL143496A0 IL143496A0 IL14349699A IL14349699A IL143496A0 IL 143496 A0 IL143496 A0 IL 143496A0 IL 14349699 A IL14349699 A IL 14349699A IL 14349699 A IL14349699 A IL 14349699A IL 143496 A0 IL143496 A0 IL 143496A0
- Authority
- IL
- Israel
- Prior art keywords
- gnrh
- controlled release
- release formulation
- formulation
- controlled
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9826662A GB2344287A (en) | 1998-12-03 | 1998-12-03 | Controlled release pharmaceutical formulation |
| PCT/GB1999/004045 WO2000032218A1 (en) | 1998-12-03 | 1999-12-02 | Controlled release formulation comprising gnrh-ii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL143496A0 true IL143496A0 (en) | 2002-04-21 |
Family
ID=10843631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14349699A IL143496A0 (en) | 1998-12-03 | 1999-12-02 | Controlled release formulation comprising gnrh-ii |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1140133A1 (es) |
| JP (1) | JP2002531411A (es) |
| KR (1) | KR20010089538A (es) |
| CN (1) | CN1332635A (es) |
| AU (1) | AU770676B2 (es) |
| BR (1) | BR9915943A (es) |
| CA (1) | CA2353798A1 (es) |
| CZ (1) | CZ20011893A3 (es) |
| EE (1) | EE200100293A (es) |
| GB (1) | GB2344287A (es) |
| HR (1) | HRP20010421A2 (es) |
| HU (1) | HUP0104943A3 (es) |
| IL (1) | IL143496A0 (es) |
| MX (1) | MXPA01005543A (es) |
| NO (1) | NO20012636L (es) |
| NZ (1) | NZ511984A (es) |
| PL (1) | PL348575A1 (es) |
| RU (1) | RU2233170C2 (es) |
| SK (1) | SK7552001A3 (es) |
| TR (1) | TR200102273T2 (es) |
| WO (1) | WO2000032218A1 (es) |
| ZA (1) | ZA200104530B (es) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8334258B2 (en) | 2005-07-26 | 2012-12-18 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts (Universitätsmedizin) | Method for induction and enhancement of apoptosis in tumor cells |
| GB0616111D0 (en) | 2006-06-16 | 2006-09-20 | Ardana Bioscience Ltd | Agents, methods and uses |
| US8563513B2 (en) | 2009-03-27 | 2013-10-22 | Van Andel Research Institute | Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use |
| WO2011032099A1 (en) | 2009-09-11 | 2011-03-17 | The Board Of Trustees Of The University Of Illinois | Methods of treating diastolic dysfunction and related conditions |
| WO2011056572A1 (en) | 2009-10-27 | 2011-05-12 | The Board Of Trustees Of The University Of Illinois | Methods of diagnosing diastolic dysfunction |
| US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| CA2788304A1 (en) | 2010-01-27 | 2011-08-04 | Indiana University Research And Technology Corporation | Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity |
| ES2575160T3 (es) | 2010-03-15 | 2016-06-24 | The Board Of Trustees Of The University Of Illinois | Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G |
| US8940860B2 (en) | 2010-06-16 | 2015-01-27 | Indiana University Research And Technology Corporation | Single-chain insulin agonists exhibiting high activity at the insulin receptor |
| US20120004182A1 (en) | 2010-07-02 | 2012-01-05 | Carsten Gruendker | Pharmaceutical compositions and methods for induction and enhancement of apoptosis in tumor cells |
| US9029502B2 (en) | 2010-12-20 | 2015-05-12 | The Regents Of The University Of Michigan | Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction |
| WO2012088116A2 (en) | 2010-12-22 | 2012-06-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
| EP2723367B1 (en) | 2011-06-22 | 2017-05-03 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| WO2013055791A1 (en) | 2011-10-10 | 2013-04-18 | The Regents Of The University Of Michigan | Polymeric nanoparticles for ultrasound imaging and therapy |
| US8859491B2 (en) | 2011-11-17 | 2014-10-14 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
| EP2793932B1 (en) | 2011-12-20 | 2018-10-03 | Indiana University Research and Technology Corporation | Ctp-based insulin analogs for treatment of diabetes |
| CN104619350A (zh) | 2012-06-14 | 2015-05-13 | Ambrx公司 | 结合到核受体配体多肽的抗psma抗体 |
| CA2877127A1 (en) | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Analogs of glucagon exhibiting gip receptor activity |
| JP6311708B2 (ja) | 2012-06-21 | 2018-04-18 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | Ｇｉｐ受容体活性を示すグルカゴンアナローグ |
| CA2886228A1 (en) | 2012-09-26 | 2014-04-03 | Indiana University Research And Technology Corporation | Insulin analog dimers |
| CA2904332A1 (en) | 2013-03-14 | 2014-10-02 | Indiana University Research And Technology Corporation | Insulin-incretin conjugates |
| WO2015120187A1 (en) | 2014-02-05 | 2015-08-13 | The University Of Chicago | Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants |
| EP3206710B1 (en) | 2014-09-24 | 2020-05-06 | Indiana University Research & Technology Corporation | Incretin-insulin conjugates |
| EP3250609A4 (en) | 2015-01-26 | 2018-07-11 | The University of Chicago | Il13ra alpha 2 binding agents and use thereof in cancer treatment |
| JP6912386B2 (ja) | 2015-01-26 | 2021-08-04 | ザ ユニバーシティー オブ シカゴ | 癌特異的なＩＬ１３Ｒα２を認識するＣＡＲ Ｔ細胞 |
| CN104789524A (zh) * | 2015-04-30 | 2015-07-22 | 四川大学 | 骨质疏松大鼠原代成骨细胞分离培养方法及应用 |
| WO2017024111A1 (en) | 2015-08-04 | 2017-02-09 | The University Of Chicago | Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6 |
| JP2020505379A (ja) * | 2017-01-20 | 2020-02-20 | イミューン システム レギュレェイション ホールディング エービー | 新規化合物（イムノレリン） |
| MA49508A (fr) | 2017-06-30 | 2020-05-06 | Amgen Inc | Procédés de traitement d'une insuffisance cardiaque avec des activateurs de sarcomères cardiaques |
| PT3661954T (pt) | 2017-08-03 | 2022-04-14 | Amgen Inc | Muteínas de interleuquina-21 e métodos de tratamento |
| TWI731264B (zh) | 2017-09-08 | 2021-06-21 | 美商安進公司 | Kras g12c抑制劑以及其使用方法 |
| GB202103867D0 (en) | 2017-09-18 | 2021-05-05 | Univ California | Claudin6 antibodies and methods of treating cancer |
| WO2019140196A1 (en) | 2018-01-12 | 2019-07-18 | Amgen Inc. | Anti-pd-1 antibodies and methods of treatment |
| US20200085776A1 (en) | 2018-09-10 | 2020-03-19 | Cardax, Inc. | Methods of Reducing C-Reactive Protein and/or Treating Cardiovascular Disease |
| WO2020191344A1 (en) | 2019-03-20 | 2020-09-24 | The Regents Of The University Of California | Claudin-6 bispecific antibodies |
| CA3134055A1 (en) | 2019-03-20 | 2020-09-24 | The Regents Of The University Of California | Claudin-6 antibodies and drug conjugates |
| CN112955181A (zh) * | 2019-03-26 | 2021-06-11 | 新型医药公司 | 一种长效脂肪酸缀合的GnRH衍生物及含其的药物组合物 |
| WO2020210376A1 (en) | 2019-04-09 | 2020-10-15 | The Board Of Trustees Of The University Of Illinois | Drug adsorbed highly porous activated carbon for enhanced drug delivery |
| US20230190725A1 (en) | 2019-04-29 | 2023-06-22 | The Board Of Trustees Of The University Of Illinois | Mek inhibitors for corneal scarring and neovascularization |
| WO2020222668A1 (en) | 2019-04-30 | 2020-11-05 | Instituto de Medicina Molecular João Lobo Antunes | Rank pathway inhibitors in combination with cdk inhibitors |
| AU2020303986A1 (en) | 2019-06-24 | 2021-12-09 | Amgen Inc. | Inhibition of SIRP-gamma for cancer treatment |
| WO2021042048A1 (en) | 2019-08-30 | 2021-03-04 | Research Institute At Nationwide Children's Hospital | Copper-atsm for treating neurodegenerative disorders associated with mitochondrial dysfunction |
| TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷 |
| WO2022159575A1 (en) | 2021-01-20 | 2022-07-28 | Bioentre Llc | Ctla4-binding proteins and methods of treating cancer |
| WO2023137161A1 (en) | 2022-01-14 | 2023-07-20 | Amgen Inc. | Triple blockade of tigit, cd112r, and pd-l1 |
| US11986474B1 (en) | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH661206A5 (fr) * | 1983-09-23 | 1987-07-15 | Debiopharm Sa | Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes. |
| DE3414595A1 (de) * | 1984-04-18 | 1985-10-31 | Hoechst Ag, 6230 Frankfurt | Verwendung von gonadoliberin und gonadoliberinagonisten zur behandlung klimakterischer beschwerden |
| US4540513A (en) * | 1984-09-25 | 1985-09-10 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Decapeptide having gonadotropin releasing activity |
| US4721775A (en) * | 1985-08-26 | 1988-01-26 | Board Of Regents, The University Of Texas System | Effective peptides related to the luteinizing hormone releasing hormone from L-amino acids |
| NZ240214A (en) * | 1990-10-16 | 1993-02-25 | Takeda Chemical Industries Ltd | Polymer compositions comprising a polylactic acid and a copolymer of glycolic acid and a hydroxycarboxylic acid; use as carrier for prolonged release pharmaceutical compositions of water soluble drugs |
| IT1243390B (it) * | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
| CA2192773C (en) * | 1995-12-15 | 2008-09-23 | Hiroaki Okada | Production of sustained-release preparation for injection |
| AU3388597A (en) * | 1996-06-13 | 1998-01-07 | University Of Cape Town | Human type ii gonadotropin-releasing hormone receptor |
-
1998
- 1998-12-03 GB GB9826662A patent/GB2344287A/en not_active Withdrawn
-
1999
- 1999-12-02 TR TR2001/02273T patent/TR200102273T2/xx unknown
- 1999-12-02 CN CN99815183A patent/CN1332635A/zh active Pending
- 1999-12-02 EP EP99958357A patent/EP1140133A1/en not_active Withdrawn
- 1999-12-02 EE EEP200100293A patent/EE200100293A/xx unknown
- 1999-12-02 IL IL14349699A patent/IL143496A0/xx unknown
- 1999-12-02 RU RU2001118040/15A patent/RU2233170C2/ru not_active IP Right Cessation
- 1999-12-02 CA CA002353798A patent/CA2353798A1/en not_active Abandoned
- 1999-12-02 PL PL99348575A patent/PL348575A1/xx not_active Application Discontinuation
- 1999-12-02 BR BR9915943-0A patent/BR9915943A/pt not_active IP Right Cessation
- 1999-12-02 KR KR1020017006883A patent/KR20010089538A/ko not_active Application Discontinuation
- 1999-12-02 JP JP2000584909A patent/JP2002531411A/ja active Pending
- 1999-12-02 SK SK755-2001A patent/SK7552001A3/sk unknown
- 1999-12-02 HU HU0104943A patent/HUP0104943A3/hu unknown
- 1999-12-02 WO PCT/GB1999/004045 patent/WO2000032218A1/en not_active Application Discontinuation
- 1999-12-02 AU AU15732/00A patent/AU770676B2/en not_active Ceased
- 1999-12-02 NZ NZ511984A patent/NZ511984A/xx unknown
- 1999-12-02 CZ CZ20011893A patent/CZ20011893A3/cs unknown
- 1999-12-02 MX MXPA01005543A patent/MXPA01005543A/es unknown
-
2001
- 2001-05-29 NO NO20012636A patent/NO20012636L/no not_active Application Discontinuation
- 2001-06-01 ZA ZA200104530A patent/ZA200104530B/en unknown
- 2001-06-01 HR HR20010421A patent/HRP20010421A2/hr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1332635A (zh) | 2002-01-23 |
| JP2002531411A (ja) | 2002-09-24 |
| HUP0104943A2 (en) | 2002-06-29 |
| GB2344287A (en) | 2000-06-07 |
| NO20012636L (no) | 2001-07-12 |
| TR200102273T2 (tr) | 2001-12-21 |
| WO2000032218A1 (en) | 2000-06-08 |
| RU2233170C2 (ru) | 2004-07-27 |
| NO20012636D0 (no) | 2001-05-29 |
| ZA200104530B (en) | 2002-06-04 |
| EP1140133A1 (en) | 2001-10-10 |
| HUP0104943A3 (en) | 2002-08-28 |
| HRP20010421A2 (en) | 2002-06-30 |
| AU1573200A (en) | 2000-06-19 |
| SK7552001A3 (en) | 2002-02-05 |
| MXPA01005543A (es) | 2003-07-14 |
| BR9915943A (pt) | 2001-08-21 |
| KR20010089538A (ko) | 2001-10-06 |
| GB9826662D0 (en) | 1999-01-27 |
| NZ511984A (en) | 2002-11-26 |
| CZ20011893A3 (cs) | 2002-05-15 |
| AU770676B2 (en) | 2004-02-26 |
| EE200100293A (et) | 2002-08-15 |
| PL348575A1 (en) | 2002-06-03 |
| CA2353798A1 (en) | 2000-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL348575A1 (en) | Controlled release formulation comprising gnrh-ii | |
| EG24198A (en) | Extended release formulation | |
| SG71879A1 (en) | Controlled release compositions | |
| SG93831A1 (en) | Polimeric controlled release compositions | |
| EP1107735A4 (en) | FORMULATION OF OMEPRAZOLE | |
| PL343021A1 (en) | Formulations | |
| PL346423A1 (en) | Microcapsule formulations | |
| SG71789A1 (en) | Controlled release compositions | |
| EG24226A (en) | Formulation | |
| IL135457A0 (en) | Extended release formulation | |
| PL346414A1 (en) | Microcapsule formulations | |
| SG72947A1 (en) | Controlled release compositions | |
| GB9905898D0 (en) | Controlled-dose formulation | |
| GB9902304D0 (en) | Formulation | |
| GB2334486B (en) | Release unit | |
| GB2322867B (en) | Release agent | |
| GB9810180D0 (en) | Novel formulation | |
| GB9927614D0 (en) | Sterliant formulation | |
| GB9815002D0 (en) | Formulations | |
| GB9815001D0 (en) | Formulations | |
| GB9711946D0 (en) | Release devices | |
| GB9816563D0 (en) | Controlled release formulations | |
| GB9404544D0 (en) | Controlled release formulation | |
| GB9902236D0 (en) | Formulation | |
| GB9916958D0 (en) | Controlled release formulations |